FDA Warning Letters Target Five Online Peptide Vendors
FDA issued warning letters to five online peptide sellers for unapproved GLP-1 drugs, with responses due within 15 working days of receipt.
PepNews
Commentary Warns FDA Fails to Stop Online Peptide Sales
A FinancialContent opinion piece argues online sellers continue marketing unapproved retatrutide despite FDA warning letters, citing an enforcement gap.
Fox News Opinion Piece Flags China-to-US Retatrutide Pipeline
A Fox News opinion essay describes retatrutide, an investigational drug in Phase 3 trials, being shipped from China into US homes via gray-market channels.
PSM Tracks 50 State Board Actions, 160 FDA Letters on GLP-1 Compounders
The Partnership for Safe Medicines has documented 50 state pharmacy board actions and 160 FDA letters targeting unsafe GLP-1 and peptide compounders since 2025.
FDA Warns Five Online Peptide Vendors Over Unapproved GLP-1 Drugs
The FDA issued warning letters to five online peptide vendors, citing the alleged sale of unapproved GLP-1 drugs and research peptides directly to consumers.
FDA Approves Mounjaro to Cut CV Risk in Type 2 Diabetes
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk, based on SURPASS-CVOT trial results.
Qatar MOPH Bans Handling of Unlicensed Peptide Products
Qatar's MOPH issued Circular PDC/2026/31 prohibiting handling, distribution, use, and promotion of unlicensed peptide products, effective immediately.
Federal Appeals Court Upholds FDA GLP-1 Shortage-End Rulings
A federal appeals court ruled the FDA followed proper process in ending GLP-1 shortage declarations, dealing a loss to compounders challenging the agency.
NBC News Finds No National System Tracks Peptide Adverse Events
NBC News finds the U.S. lacks a comprehensive system for tracking peptide adverse events, leaving safety gaps beyond approved GLP-1 drugs.
Sheppard Mullin: PCAC Peptide Votes Advisory Only, Rulemaking Likely to 2027–2028
A new legal analysis confirms FDA's advisory committee votes on six peptides for the 503A Bulks List are nonbinding, with formal rulemaking likely extending into 2027 or 2028.
